Safety study on PCI 32765 in combination with bortezomib in patients with mantle cell lymphoma.

Trial Profile

Safety study on PCI 32765 in combination with bortezomib in patients with mantle cell lymphoma.

Not stated
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Bortezomib; Ibrutinib
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 19 Nov 2013 Status changed from planning to unconfirmed.
    • 07 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top